The analysis included 98,147 GLP-1 RA users and approximately 2.49 million DPP-4i users, with a median follow-up ranging from 1.8 to 3 years. HealthDay News — Glucagon-like peptide 1 receptor ...
Opens in a new tab or window More thyroid cancers were detected soon after starting a GLP-1 receptor agonist than other diabetes drugs, a secondary analysis of a target trial emulation of a ...